Literature DB >> 11119169

Adherence to guidelines for oral anticoagulation after venous thrombosis and pulmonary embolism.

D A Ganz1, R J Glynn, H Mogun, E L Knight, R L Bohn, J Avorn.   

Abstract

OBJECTIVE: Guidelines for oral anticoagulation after deep venous thrombosis (DVT) or pulmonary embolism (PE) have recommended that patients be anticoagulated for at least 3 months after hospital discharge. We sought to determine whether this recommendation was being followed and what patient characteristics predict a shorter than recommended duration of therapy.
DESIGN: Retrospective cohort study using linked health care claims data.
SETTING: Routine clinical practice. PATIENTS: Five hundred seventy-three members of New Jersey's Medicaid or Pharmacy Assistance for the Aged and Disabled programs aged 65 years and older who were hospitalized for DVT or PE between January 1, 1991 and June 30, 1994.
RESULTS: Of the 573 patients, 129 (23%) filled prescriptions covering less than 90 days of oral anticoagulant therapy. In multivariate models, African-American race was associated with an increased risk of a shorter than recommended duration of therapy (odds ratio [OR], 1.87; 95% confidence interval [CI], 1.14 to 3.08), but age and gender were not. Patients who used anticoagulants in the year prior to admission were less likely to have a short duration of therapy (OR, 0.30; 95% CI, 0.12 to 0.78), than were patients with PE (OR, 0.58; 95% CI, 0.38 to 0.88).
CONCLUSIONS: Nearly a quarter of those anticoagulated following DVT or PE received therapy for less than the recommended length of time after hospital discharge, with African Americans more likely to have a shorter than recommended course of treatment. Further research is needed to evaluate the causes of shorter than recommended duration of therapy and racial disparities in anticoagulant use.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11119169      PMCID: PMC1495613          DOI: 10.1046/j.1525-1497.2000.91022.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  26 in total

1.  Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'.

Authors:  P O Hansson; L Welin; G Tibblin; H Eriksson
Journal:  Arch Intern Med       Date:  1997 Aug 11-25

2.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

Review 3.  Pulmonary embolism.

Authors:  S Z Goldhaber
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

4.  Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California.

Authors:  R H White; H Zhou; P S Romano
Journal:  Ann Intern Med       Date:  1998-05-01       Impact factor: 25.391

Review 5.  Management of venous thromboembolism.

Authors:  J S Ginsberg
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

6.  The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; S Granqvist; M Holmström; A Carlsson; P Lindmarker; P Nicol; S G Eklund; S Nordlander; G Lärfars; B Leijd; O Linder; E Loogna
Journal:  N Engl J Med       Date:  1997-02-06       Impact factor: 91.245

7.  A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

Authors:  S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter
Journal:  N Engl J Med       Date:  1995-06-22       Impact factor: 91.245

8.  Determinants of compliance with anticoagulation: A case-control study.

Authors:  J H Arnsten; J M Gelfand; D E Singer
Journal:  Am J Med       Date:  1997-07       Impact factor: 4.965

9.  Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.

Authors:  P M Ridker; R J Glynn; J P Miletich; S Z Goldhaber; M J Stampfer; C H Hennekens
Journal:  Ann Intern Med       Date:  1997-04-01       Impact factor: 25.391

10.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.

Authors:  M D Silverstein; J A Heit; D N Mohr; T M Petterson; W M O'Fallon; L J Melton
Journal:  Arch Intern Med       Date:  1998-03-23
View more
  10 in total

1.  Guidelines for anticoagulation therapy for venous thromboembolism.

Authors:  David K Cundiff
Journal:  J Gen Intern Med       Date:  2002-01       Impact factor: 5.128

2.  Guidelines for warfarin therapy following a thromboembolic event.

Authors:  S K Sutton
Journal:  J Gen Intern Med       Date:  2001-05       Impact factor: 5.128

3.  Venous thromboembolism after major orthopaedic surgery: a population-based cohort study.

Authors:  Davide Imberti; Cosetta Bianchi; Antonella Zambon; Andrea Parodi; Luca Merlino; Massimo Gallerani; Giovanni Corrao
Journal:  Intern Emerg Med       Date:  2011-03-26       Impact factor: 3.397

4.  Primary medication non-adherence: analysis of 195,930 electronic prescriptions.

Authors:  Michael A Fischer; Margaret R Stedman; Joyce Lii; Christine Vogeli; William H Shrank; M Alan Brookhart; Joel S Weissman
Journal:  J Gen Intern Med       Date:  2010-02-04       Impact factor: 5.128

5.  Simulation curriculum can improve medical student assessment and management of acute coronary syndrome during a clinical practice exam.

Authors:  Deborah J DeWaay; Matthew D McEvoy; Donna H Kern; Louise A Alexander; Paul J Nietert
Journal:  Am J Med Sci       Date:  2014-06       Impact factor: 2.378

6.  Racial differences in 30-day mortality for pulmonary embolism.

Authors:  Said A Ibrahim; Roslyn A Stone; D Scott Obrosky; Jennifer Sartorius; Michael J Fine; Drahomir Aujesky
Journal:  Am J Public Health       Date:  2006-10-31       Impact factor: 9.308

7.  Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.

Authors:  François Laliberté; Brahim K Bookhart; Winnie W Nelson; Patrick Lefebvre; Jeff R Schein; Jonathan Rondeau-Leclaire; Mei Sheng Duh
Journal:  Patient       Date:  2013       Impact factor: 3.883

8.  The adherence to initial processes of care in elderly patients with acute venous thromboembolism.

Authors:  Anna K Stuck; Marie Méan; Andreas Limacher; Marc Righini; Kurt Jaeger; Hans-Jürg Beer; Joseph Osterwalder; Beat Frauchiger; Christian M Matter; Nils Kucher; Michael Egloff; Markus Aschwanden; Marc Husmann; Anne Angelillo-Scherrer; Nicolas Rodondi; Drahomir Aujesky
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

9.  Unintended discontinuation of medication following hospitalisation: a retrospective cohort study.

Authors:  Patrick Redmond; Ronald McDowell; Tamasine C Grimes; Fiona Boland; Ronan McDonnell; Carmel Hughes; Tom Fahey
Journal:  BMJ Open       Date:  2019-06-04       Impact factor: 2.692

10.  Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register.

Authors:  Emilia Antonucci; Ludovica Migliaccio; Maria Abbattista; Antonella Caronna; Sergio De Marchi; Angela Di Giorgio; Rosella Di Giulio; Teresa Lerede; Maria Grazia Garzia; Ida Martinelli; Daniela Mastroiacovo; Marco Marzolo; Elisa Montevecchi; Daniele Pastori; Pasquale Pignatelli; Daniela Poli; Luigi Ria; Angelo Santoliquido; Sophie Testa; Gualtiero Palareti
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.